Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 106

1.

Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma.

Feng M, Gao W, Wang R, Chen W, Man YG, Figg WD, Wang XW, Dimitrov DS, Ho M.

Proc Natl Acad Sci U S A. 2013 Mar 19;110(12):E1083-91. doi: 10.1073/pnas.1217868110. Epub 2013 Mar 5.

PMID:
23471984
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Anti-glypican 3 antibodies cause ADCC against human hepatocellular carcinoma cells.

Nakano K, Orita T, Nezu J, Yoshino T, Ohizumi I, Sugimoto M, Furugaki K, Kinoshita Y, Ishiguro T, Hamakubo T, Kodama T, Aburatani H, Yamada-Okabe H, Tsuchiya M.

Biochem Biophys Res Commun. 2009 Jan 9;378(2):279-84. doi: 10.1016/j.bbrc.2008.11.033. Epub 2008 Nov 18.

PMID:
19022220
[PubMed - indexed for MEDLINE]
3.

Suppression of glypican 3 inhibits growth of hepatocellular carcinoma cells through up-regulation of TGF-β2.

Sun CK, Chua MS, He J, So SK.

Neoplasia. 2011 Aug;13(8):735-47.

PMID:
21847365
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Inactivation of Wnt signaling by a human antibody that recognizes the heparan sulfate chains of glypican-3 for liver cancer therapy.

Gao W, Kim H, Feng M, Phung Y, Xavier CP, Rubin JS, Ho M.

Hepatology. 2014 Aug;60(2):576-87. doi: 10.1002/hep.26996. Epub 2014 Jun 18.

PMID:
24492943
[PubMed - indexed for MEDLINE]
5.

Inhibition of glypican-3 expression via RNA interference influences the growth and invasive ability of the MHCC97-H human hepatocellular carcinoma cell line.

Ruan J, Liu F, Chen X, Zhao P, Su N, Xie G, Chen J, Zheng D, Luo R.

Int J Mol Med. 2011 Oct;28(4):497-503. doi: 10.3892/ijmm.2011.704. Epub 2011 May 20.

PMID:
21617840
[PubMed - indexed for MEDLINE]
6.

High-affinity monoclonal antibodies to cell surface tumor antigen glypican-3 generated through a combination of peptide immunization and flow cytometry screening.

Phung Y, Gao W, Man YG, Nagata S, Ho M.

MAbs. 2012 Sep-Oct;4(5):592-9. doi: 10.4161/mabs.20933. Epub 2012 Jul 23.

PMID:
22820551
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Molecular mechanism of hepatocellular carcinoma-specific antitumor activity of the novel thienopyridine derivative TP58.

Zhou R, Huang WJ, Guo ZY, Li L, Zeng XR, Deng YQ, Hu FY, Tong AP, Yang L, Yang JL.

Oncol Rep. 2012 Jul;28(1):225-31. doi: 10.3892/or.2012.1776. Epub 2012 Apr 23.

PMID:
22552608
[PubMed - indexed for MEDLINE]
8.

Histopathological analyses of the antitumor activity of anti-glypican-3 antibody (GC33) in human liver cancer xenograft models: The contribution of macrophages.

Takai H, Kato A, Kinoshita Y, Ishiguro T, Takai Y, Ohtani Y, Sugimoto M, Suzuki M.

Cancer Biol Ther. 2009 May;8(10):930-8. Epub 2009 May 10.

PMID:
19276671
[PubMed - indexed for MEDLINE]
Free Article
9.

Phosphodiesterase 3/4 inhibitor zardaverine exhibits potent and selective antitumor activity against hepatocellular carcinoma both in vitro and in vivo independently of phosphodiesterase inhibition.

Sun L, Quan H, Xie C, Wang L, Hu Y, Lou L.

PLoS One. 2014 Mar 5;9(3):e90627. doi: 10.1371/journal.pone.0090627. eCollection 2014.

PMID:
24598942
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma.

Zhu AX, Gold PJ, El-Khoueiry AB, Abrams TA, Morikawa H, Ohishi N, Ohtomo T, Philip PA.

Clin Cancer Res. 2013 Feb 15;19(4):920-8. doi: 10.1158/1078-0432.CCR-12-2616. Epub 2013 Jan 29.

PMID:
23362325
[PubMed - indexed for MEDLINE]
Free Article
11.

Glypican-3 antibodies: a new therapeutic target for liver cancer.

Feng M, Ho M.

FEBS Lett. 2014 Jan 21;588(2):377-82. doi: 10.1016/j.febslet.2013.10.002. Epub 2013 Oct 15. Review.

PMID:
24140348
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Cellular changes resulting from forced expression of glypican-3 in hepatocellular carcinoma cells.

Kwack MH, Choi BY, Sung YK.

Mol Cells. 2006 Apr 30;21(2):224-8.

PMID:
16682817
[PubMed - indexed for MEDLINE]
Free Article
13.

Glypican-3: a marker and a therapeutic target in hepatocellular carcinoma.

Filmus J, Capurro M.

FEBS J. 2013 May;280(10):2471-6. doi: 10.1111/febs.12126. Epub 2013 Jan 31. Review.

PMID:
23305321
[PubMed - indexed for MEDLINE]
14.

The glypican 3 hepatocellular carcinoma marker regulates human hepatic stellate cells via Hedgehog signaling.

Magistri P, Leonard SY, Tang CM, Chan JC, Lee TE, Sicklick JK.

J Surg Res. 2014 Apr;187(2):377-85. doi: 10.1016/j.jss.2013.12.010. Epub 2013 Dec 17.

PMID:
24439425
[PubMed - indexed for MEDLINE]
15.

Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling.

Capurro MI, Xiang YY, Lobe C, Filmus J.

Cancer Res. 2005 Jul 15;65(14):6245-54.

PMID:
16024626
[PubMed - indexed for MEDLINE]
Free Article
16.

Glypican-3: a new target for cancer immunotherapy.

Ho M, Kim H.

Eur J Cancer. 2011 Feb;47(3):333-8. doi: 10.1016/j.ejca.2010.10.024. Epub 2010 Nov 26. Review.

PMID:
21112773
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model.

Wang C, Gao D, Guo K, Kang X, Jiang K, Sun C, Li Y, Sun L, Shu H, Jin G, Sun H, Wu W, Liu Y.

BMC Cancer. 2012 May 4;12:166. doi: 10.1186/1471-2407-12-166.

PMID:
22559167
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Overexpression of ZFX confers self-renewal and chemoresistance properties in hepatocellular carcinoma.

Lai KP, Chen J, He M, Ching AK, Lau C, Lai PB, To KF, Wong N.

Int J Cancer. 2014 Oct 15;135(8):1790-9. doi: 10.1002/ijc.28819. Epub 2014 Mar 11.

PMID:
24585547
[PubMed - indexed for MEDLINE]
19.

A functional screening identifies five microRNAs controlling glypican-3: role of miR-1271 down-regulation in hepatocellular carcinoma.

Maurel M, Jalvy S, Ladeiro Y, Combe C, Vachet L, Sagliocco F, Bioulac-Sage P, Pitard V, Jacquemin-Sablon H, Zucman-Rossi J, Laloo B, Grosset CF.

Hepatology. 2013 Jan;57(1):195-204. doi: 10.1002/hep.25994.

PMID:
22865282
[PubMed - indexed for MEDLINE]
20.

Inhibitory effect of oleanolic acid on hepatocellular carcinoma via ERK-p53-mediated cell cycle arrest and mitochondrial-dependent apoptosis.

Wang X, Bai H, Zhang X, Liu J, Cao P, Liao N, Zhang W, Wang Z, Hai C.

Carcinogenesis. 2013 Jun;34(6):1323-30. doi: 10.1093/carcin/bgt058. Epub 2013 Feb 12.

PMID:
23404993
[PubMed - indexed for MEDLINE]
Free Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk